MCID: TTN003
MIFTS: 66

Tetanus

Categories: Bone diseases, Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tetanus

MalaCards integrated aliases for Tetanus:

Name: Tetanus 12 77 54 60 56 44 3 3 45 15 17 74
Lockjaw 54 3
Infection Due to Clostridium Tetani 12
Clostridial Tetanus 12

Characteristics:

Orphanet epidemiological data:

60
tetanus
Prevalence: <1/1000000 (France),<1/1000000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:11338
ICD9CM 36 037
MeSH 45 D013742
NCIt 51 C85185
SNOMED-CT 69 76902006
ICD10 34 A35
MESH via Orphanet 46 D013742
ICD10 via Orphanet 35 A33 A34 A35
UMLS via Orphanet 75 C0039614
Orphanet 60 ORPHA3299
UMLS 74 C0039614

Summaries for Tetanus

MedlinePlus : 44 Tetanus is a serious illness caused by Clostridium bacteria. The bacteria live in soil, saliva, dust, and manure. The bacteria can enter the body through a deep cut, like those you might get from stepping on a nail, or through a burn. The infection causes painful tightening of the muscles, usually all over the body. It can lead to "locking" of the jaw. This makes it impossible to open your mouth or swallow. Tetanus is a medical emergency. You need to get treatment in a hospital. A vaccine can prevent tetanus. It is given as a part of routine childhood immunization. Adults should get a tetanus shot, or booster, every 10 years. If you get a bad cut or burn, see your doctor - you may need a booster. Immediate and proper wound care can prevent tetanus infection.

MalaCards based summary : Tetanus, also known as lockjaw, is related to diphtheria and poliomyelitis, and has symptoms including fever and pruritus. An important gene associated with Tetanus is VAMP7 (Vesicle Associated Membrane Protein 7), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Abatacept and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and b cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A primary bacterial infectious disease that results in prolonged contraction of skeletal muscle fibers, has material basis in Clostridium tetani, which produces tetanospasmin, a neurotoxin, which is carried to the brain and spinal cord, where it binds irreversibly to receptors inhibiting neurotransmission. Damaged upper motor neurons cannot control reflex responses to afferent sensory stimuli.

CDC : 3 Tetanus is an infection caused by bacteria called Clostridium tetani. When the bacteria invade the body, they produce a poison (toxin) that causes painful muscle contractions. Another name for tetanus is “lockjaw”. It often causes a person’s neck and jaw muscles to lock, making it hard to open the mouth or swallow. CDC recommends vaccines for infants, children, teens, and adults to prevent tetanus.

Wikipedia : 77 Tetanus, also known as lockjaw, is a bacterial infection characterized by muscle spasms. In the most... more...

Related Diseases for Tetanus

Diseases related to Tetanus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 427)
# Related Disease Score Top Affiliating Genes
1 diphtheria 33.0 IL13 IL2 IL2RA
2 poliomyelitis 31.5 IFNG IL10 IL4
3 variola major 31.0 IFNG IL2
4 mumps 30.9 IFNG IL2 IL2RA
5 rubella 30.8 CD40LG IL10 IL4
6 lepromatous leprosy 30.5 IFNG IL10 IL2
7 human immunodeficiency virus infectious disease 30.4 IFNG IL10 IL2
8 pneumonia 30.3 CD40LG IL10 IL13 IL5
9 herpes zoster 30.3 IFNG IL10 IL2
10 onchocerciasis 30.2 IL13 IL2 IL4 IL5
11 yellow fever 30.2 IL4 IL5 LTA
12 leprosy 3 30.2 IFNG IL10 IL2
13 filarial elephantiasis 30.1 IL10 IL4 IL5
14 relapsing-remitting multiple sclerosis 30.1 IFNG IL10 IL4
15 myasthenia gravis 30.1 IFNG IL10 IL2 IL4
16 filariasis 30.0 IFNG IL10 IL2 IL5
17 hematopoietic stem cell transplantation 30.0 IFNG IL10 IL2
18 wells syndrome 30.0 IL2 IL2RA IL5
19 multiple sclerosis 29.9 IFNG IL10 IL2 IL2RA IL4 LTA
20 rheumatic disease 29.9 CD40LG IFNG IL10 IL2RA
21 bone inflammation disease 29.8 IFNG IL10 IL2 IL4
22 human immunodeficiency virus type 1 29.8 CCR7 IFNG IL10 IL2 LTA
23 milk allergy 29.8 CD79A IL10 IL4 IL5
24 malaria 29.8 CD40LG IFNG IL10 IL13 IL2 IL4
25 dermatitis 29.8 IFNG IL13 IL4 IL5
26 rheumatoid arthritis 29.6 CD40LG IFNG IL10 IL2 IL2RA IL4
27 inflammatory bowel disease 29.6 IFNG IL10 IL13 IL2 IL4
28 keratoconjunctivitis 29.6 IFNG IL13 IL2 IL4 IL5
29 ige responsiveness, atopic 29.6 IFNG IL10 IL13 IL4 IL5
30 allergic hypersensitivity disease 29.5 IFNG IL10 IL13 IL4 IL5
31 schistosomiasis 29.5 CD40LG IFNG IL10 IL13 IL2 IL4
32 allergic rhinitis 29.5 IFNG IL10 IL13 IL4 IL5
33 sarcoidosis 1 29.5 IFNG IL13 IL2 IL2RA LTA
34 asthma 29.4 CD40LG IFNG IL10 IL13 IL2RA IL4
35 systemic lupus erythematosus 28.9 CD40LG CD79A IFNG IL10 IL2 IL2RA
36 tetanus neonatorum 12.7
37 pertussis 11.1
38 immunodeficiency 25 11.1
39 specific antibody deficiency 11.1
40 haemophilus influenzae 10.9
41 hepatitis 10.7
42 hepatitis b 10.7
43 berylliosis 10.6 IFNG IL2
44 b-cell growth factor 10.6 IFNG IL4
45 measles 10.5
46 autoimmune vasculitis 10.5 IL2 IL4
47 virus associated hemophagocytic syndrome 10.5 IL2 IL4
48 tungiasis 10.5 IL10 IL4
49 streptococcal toxic-shock syndrome 10.5 IL2 LTA
50 transient hypogammaglobulinemia 10.5 IL10 LTA

Graphical network of the top 20 diseases related to Tetanus:



Diseases related to Tetanus

Symptoms & Phenotypes for Tetanus

UMLS symptoms related to Tetanus:


fever, pruritus

GenomeRNAi Phenotypes related to Tetanus according to GeneCards Suite gene sharing:

27 (show all 46)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.21 CCR7 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.21 IL13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.21 IL10
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.21 CCR7
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.21 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.21 CCR7 IL10 IL13 VAMP7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.21 IL13
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.21 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.21 VAMP7
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.21 IL10
11 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 VAMP7
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.21 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.21 CCR7
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.21 CCR7 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.21 IL13
16 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.21 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.21 CCR7
19 Increased shRNA abundance (Z-score > 2) GR00366-A-24 10.21 VAMP7
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 VAMP7
22 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.21 IL13
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.21 VAMP7
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.21 VAMP7
26 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.21 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.21 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.21 VAMP7
29 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.21 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.21 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.21 IL10
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.11 IL2RA
33 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.11 IL2RA
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.11 IL10 NSF
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.11 IL10 IL2RA NSF VAMP7
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.11 IL2RA
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 10.11 VAMP7
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.11 VAMP7
39 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.11 IL2RA
40 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.11 NSF
41 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.11 IL10 IL2RA
42 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.11 IL10
43 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.11 IL10
44 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.11 NSF
45 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG IL10 IL2 IL2RA LTA STX3
46 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD27 CD40LG IL10 IL2 IL2RA LTA

MGI Mouse Phenotypes related to Tetanus:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 CCR7 CD27 CD40LG CD79A IFNG IL10
2 homeostasis/metabolism MP:0005376 10.28 CCR7 CD40LG CD79A IFNG IL10 IL13
3 immune system MP:0005387 10.25 CCR7 CD27 CD40LG CD79A IFNG IL10
4 endocrine/exocrine gland MP:0005379 10.22 CCR7 CD40LG IFNG IL10 IL13 IL2
5 mortality/aging MP:0010768 10.13 CD40LG IFNG IL10 IL13 IL2 IL2RA
6 digestive/alimentary MP:0005381 10.1 CCR7 IFNG IL10 IL13 IL2 IL2RA
7 nervous system MP:0003631 10.03 CCR7 CD40LG CD79A IFNG IL10 IL13
8 liver/biliary system MP:0005370 9.97 CD79A IFNG IL10 IL2 IL4 IL5
9 no phenotypic analysis MP:0003012 9.81 CCR7 CD79A IFNG IL10 IL13 IL2
10 respiratory system MP:0005388 9.61 IFNG IL10 IL13 IL2 IL2RA IL4
11 vision/eye MP:0005391 9.23 CCR7 IFNG IL10 IL2 IL2RA IL4

Drugs & Therapeutics for Tetanus

Drugs for Tetanus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 347)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 2,Phase 1 332348-12-6 10237
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
3
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
4
Natalizumab Approved, Investigational Phase 4 189261-10-7
5
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
6
tannic acid Approved Phase 4,Not Applicable 1401-55-4
7
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
8
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
9
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
10
Pentetic acid Approved Phase 4,Phase 3,Phase 2 67-43-6
11
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable 174722-31-7 10201696
12
Adalimumab Approved Phase 4 331731-18-1 16219006
13
Etanercept Approved, Investigational Phase 4 185243-69-0
14
Desflurane Approved Phase 4 57041-67-5 42113
15
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
16
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
17
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
18
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
19
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
20
Sodium Citrate Approved, Investigational Phase 4 68-04-2
21
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
22
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
23
Ritonavir Approved, Investigational Phase 4,Not Applicable 155213-67-5 392622
24
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
25
Lopinavir Approved Phase 4 192725-17-0 92727
26
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
27
Tenofovir Approved, Experimental, Investigational Phase 4 147127-20-6 464205
28
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-30-3 6037
30
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
31
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
BCG vaccine Investigational Phase 4,Phase 2,Not Applicable
33 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
35 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
37 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antacids Phase 4,Phase 3,Phase 2,Phase 1
39 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Central Nervous System Depressants Phase 4,Phase 1,Not Applicable
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Antidotes Phase 4,Phase 3,Phase 2
47 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Folate Phase 4,Phase 3,Phase 2,Not Applicable
49 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Vitamin B9 Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 721)
# Name Status NCT ID Phase Drugs
1 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
2 An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster Unknown status NCT00870350 Phase 4
3 The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients Unknown status NCT00336115 Phase 4
4 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
5 Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates Unknown status NCT02179996 Phase 4
6 Pertussis (Tdap) Vaccination in Pregnancy Unknown status NCT01698346 Phase 4
7 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
8 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td Completed NCT00601835 Phase 4
9 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine Completed NCT03552445 Phase 4
10 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
11 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4 Boostrix polio
12 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
13 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
14 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed NCT00347958 Phase 4
15 Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
16 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
17 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed NCT00457249 Phase 4
18 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
19 Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine Completed NCT00674908 Phase 4
20 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed NCT00319553 Phase 4
21 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
22 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
23 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
24 Post Marketing Surveillance for ADACEL™ in South Korea Completed NCT01137435 Phase 4
25 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
26 A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants. Completed NCT01250756 Phase 4
27 Tdap Vaccine in Post-Partum Women Completed NCT01711645 Phase 4
28 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
29 Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Completed NCT00244673 Phase 4
30 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
31 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
32 Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Completed NCT02783170 Phase 4
33 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
34 Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine Completed NCT00617812 Phase 4
35 Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision Completed NCT02884310 Phase 4 Remifentanil adapted to SPI;Remifentanil fixed
36 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed NCT01357720 Phase 4
37 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. Completed NCT00610168 Phase 4
38 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
39 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
40 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
41 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
42 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
43 Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA) Completed NCT00111410 Phase 4 Anakinra (r-metHuIL-1ra)
44 Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 Completed NCT00548171 Phase 4
45 Tropical Influenza Control Strategies for the Elderly Completed NCT02655874 Phase 4
46 Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients Completed NCT00287677 Phase 4 HAART
47 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
48 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
49 Evaluation of Boostrix™10 Years After Previous Booster Vaccination Completed NCT01147900 Phase 4
50 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women Completed NCT02377349 Phase 4 Saline placebo

Search NIH Clinical Center for Tetanus

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: tetanus

Genetic Tests for Tetanus

Anatomical Context for Tetanus

MalaCards organs/tissues related to Tetanus:

42
Testes, T Cells, B Cells, Brain, Spinal Cord, Skeletal Muscle, Skin

Publications for Tetanus

Articles related to Tetanus:

(show top 50) (show all 3730)
# Title Authors Year
1
Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'. ( 31062020 )
2019
2
Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study. ( 30785851 )
2019
3
Determinants of delayed or incomplete diphtheria-tetanus-pertussis vaccination in parallel urban and rural birth cohorts of 30,956 infants in Tanzania. ( 30808282 )
2019
4
Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. ( 30814030 )
2019
5
Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry. ( 30831450 )
2019
6
Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. ( 30877773 )
2019
7
A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea. ( 30940999 )
2019
8
Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study. ( 30961907 )
2019
9
Tubercular Abscess near Diphtheria-Pertussis-Tetanus Injection Site: A Rare Complication of Immunization. ( 30983718 )
2019
10
Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children. ( 31009031 )
2019
11
Arsenic exposure and serum antibody concentrations to diphtheria and tetanus toxoid in children at age 5: A prospective birth cohort in Bangladesh. ( 31051324 )
2019
12
Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. ( 29438562 )
2019
13
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. ( 30999933 )
2019
14
Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV). ( 30381690 )
2019
15
Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines. ( 30417710 )
2019
16
Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. ( 30444673 )
2019
17
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regression. ( 30471957 )
2019
18
Use of different combination diphtheria-tetanus-acellular pertussis vaccines does not increase risk of 30-day infant mortality. A population-based linkage cohort study using administrative data from the Australian Childhood Immunisation Register and the National Death Index. ( 30503081 )
2019
19
A systematic review of adult tetanus-diphtheria-acellular (Tdap) coverage among healthcare workers. ( 30630694 )
2019
20
Neighbourhood influence on the fourth dose of diphtheria-tetanus-pertussis vaccination. ( 30639802 )
2019
21
Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children. ( 30668217 )
2019
22
A Phase III Study to Evaluate the Immunogenicity and Safety of GC1107 (Adult Tetanus Diphtheria Vaccine) in Healthy Adults. ( 30686952 )
2019
23
Development and validation of magnetic bead pentaplex immunoassay for simultaneous quantification of murine serum IgG antibodies to acellular pertussis, diphtheria and tetanus antigens used in combination vaccines. ( 30690077 )
2019
24
Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants. ( 30252603 )
2019
25
Should we believe emergency department patients self-reported tetanus vaccine status? ( 30482625 )
2019
26
Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease. ( 30607904 )
2019
27
Effects of skeletal unloading on the antibody repertoire of tetanus toxoid and/or CpG treated C57BL/6J mice. ( 30653556 )
2019
28
Accuracy of Parental-Reported Tetanus Vaccination Status for Children With Lacerations. ( 30702646 )
2019
29
The Effect of Pharmacy-Driven Education on the Amount of Appropriately Administered Tetanus Vaccines in the Emergency Department. ( 30718934 )
2019
30
scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor. ( 30770895 )
2019
31
The Quick and Dirty: A Tetanus Case Report. ( 30775666 )
2019
32
Frequency of risk factors, vaccination status and outcome of tetanus in children at the Children's Hospital Lahore. ( 30804579 )
2019
33
Is the test for irreversibility of tetanus toxoids still relevant? ( 30826145 )
2019
34
Notes from the Field: Tetanus in an Unvaccinated Child - Oregon, 2017. ( 30845120 )
2019
35
Cephalic tetanus presenting with bilateral facial palsy. ( 30866747 )
2019
36
Parents of US boy who survived tetanus after nearly $1m of care refuse vaccine. ( 30867159 )
2019
37
Submicroscopic Plasmodium infection during pregnancy is associated with reduced antibody levels to tetanus toxoid. ( 30194852 )
2019
38
Epidemiological Study of Tetanus Seropositivity Levels in Different Age Groups in Ankara Province, Turkey, 2017. ( 30175733 )
2019
39
A 28-Year-Old Woman With Tetanus. ( 30078616 )
2019
40
Prognostic factors for generalized tetanus in adults: A retrospective study in a Chinese hospital. ( 29891121 )
2019
41
A case of atraumatic tetanus developed initially with worsening headache in a woman regularly cared for chronic headache at an outpatient clinic. ( 30899478 )
2019
42
A Case of Severe Tetanus Complicated by Takotsubo Cardiomyopathy. ( 30918197 )
2019
43
Tetanus. ( 30935736 )
2019
44
Talk to Patients About: Tetanus. ( 30995333 )
2019
45
Trismus and oral haematoma, a rare presentation of tetanus. ( 31014538 )
2019
46
The role of the single interchains disulfide bond in Tetanus and Botulinum Neurotoxins and the development of anti-tetanus and anti-botulism drugs. ( 31050145 )
2019
47
Determinants of Tetanus Vaccination among Adult Immigrants: Findings from the Portuguese National Health Survey 2014. ( 31075829 )
2019
48
Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence. ( 31091978 )
2019
49
Prenatal Tetanus, Diphtheria, Acellular Pertussis Vaccination and Autism Spectrum Disorder. ( 30104424 )
2018
50
Summary of the NACI Update on Immunization in Pregnancy with Tetanus Toxoid, Reduced Diphtheria Toxoid and Reduced Acellular Pertussis (Tdap) Vaccine. ( 31007617 )
2018

Variations for Tetanus

Expression for Tetanus

Search GEO for disease gene expression data for Tetanus.

Pathways for Tetanus

Pathways related to Tetanus according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 CD27 CD40LG CD79A IFNG IL10 IL13
2
Show member pathways
13.87 CCR7 CD27 CD40LG IL10 IL13 IL2
3
Show member pathways
13.72 CCR7 CD27 CD40LG IFNG IL10 IL13
4
Show member pathways
13.54 IFNG IL10 IL13 IL2 IL2RA IL4
5
Show member pathways
13.47 CCR7 CD27 CD40LG IL10 IL13 IL2
6
Show member pathways
13.36 CD27 CD40LG IFNG IL10 IL13 IL2
7
Show member pathways
13.34 CCR7 CD27 CD40LG IL10 IL13 IL2
8
Show member pathways
12.89 CD40LG IFNG IL10 IL13 IL2 IL2RA
9 12.86 IFNG IL13 IL2 IL2RA IL4 IL5
10
Show member pathways
12.72 CD40LG CD79A IFNG IL10 IL2 IL2RA
11
Show member pathways
12.67 IFNG IL10 IL13 IL2 IL2RA IL4
12
Show member pathways
12.64 CD40LG IFNG IL10 IL2 IL4 IL5
13 12.62 CD40LG CD79A IFNG IL10 IL2 IL2RA
14
Show member pathways
12.45 IFNG IL10 IL13 IL2 IL2RA IL4
15
Show member pathways
12.43 IL13 IL2 IL2RA IL5
16
Show member pathways
12.33 IFNG IL13 IL4 IL5
17
Show member pathways
12.27 IFNG IL10 IL13 IL2 IL2RA IL4
18
Show member pathways
12.26 CD40LG IFNG IL10 IL4
19 12.19 IL10 IL13 SNAP25 VAMP2
20
Show member pathways
12.16 IFNG IL10 IL13 IL2 IL2RA IL4
21
Show member pathways
12.08 IFNG IL10 IL2 LTA
22
Show member pathways
12.07 NSF SNAP25 STX3 VAMP2
23
Show member pathways
12.05 IL13 IL2 IL2RA IL5
24
Show member pathways
12 IFNG IL2 IL2RA IL4
25
Show member pathways
11.96 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
26 11.92 CCR7 CD79A IFNG IL10 IL2 IL2RA
27 11.91 IFNG IL10 IL2 IL2RA
28 11.9 IFNG IL13 IL2 IL4 IL5
29 11.87 IL2RA IL4 IL5
30 11.8 IFNG IL10 IL13 IL2 IL4
31
Show member pathways
11.77 IL2 IL2RA IL4 LTA
32
Show member pathways
11.76 CD40LG IFNG IL2 IL2RA IL4 IL5
33 11.75 IFNG IL10 IL2
34 11.72 CD40LG IL10 IL4 IL5 LTA
35 11.67 IL13 IL4 IL5
36
Show member pathways
11.67 CD40LG IFNG IL2
37
Show member pathways
11.65 IFNG IL2 IL2RA
38 11.58 CD27 CD40LG IL10
39 11.55 IL10 IL13 IL4
40 11.54 CD40LG IFNG IL10
41 11.46 IFNG IL10 IL13 IL2 IL2RA IL4
42
Show member pathways
11.44 NSF SNAP25 VAMP2
43 11.42 IFNG IL13 IL4 IL5
44 11.36 CD40LG IFNG IL2 IL2RA IL4 IL5
45 11.36 IFNG IL10 IL13 IL2 IL2RA IL4
46 11.35 IFNG IL13 IL2 IL2RA
47 11.26 IFNG IL10 IL13 IL2 IL4 IL5
48 11.21 CD40LG IL10 IL13 IL2 IL4 IL5
49 11.08 CD40LG IL10 IL13 IL2 IL4 IL5
50 10.65 SNAP25 VAMP2

GO Terms for Tetanus

Cellular components related to Tetanus according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.93 CCR7 CD27 CD40LG IL2RA VAMP3 VAMP7
2 synapse GO:0045202 9.88 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
3 phagocytic vesicle membrane GO:0030670 9.67 SNAP23 VAMP3 VAMP7
4 synaptic vesicle GO:0008021 9.67 SNAP25 STX3 VAMP2 VAMP7
5 clathrin-coated vesicle membrane GO:0030665 9.65 VAMP2 VAMP3 VAMP7
6 neuron projection GO:0043005 9.63 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
7 specific granule GO:0042581 9.56 SNAP23 STX3
8 secretory granule GO:0030141 9.56 STX3 VAMP2 VAMP3 VAMP7
9 azurophil granule GO:0042582 9.54 SNAP23 STX3
10 zymogen granule membrane GO:0042589 9.52 STX3 VAMP2
11 synaptobrevin 2-SNAP-25-syntaxin-1a-complexin I complex GO:0070032 9.43 SNAP25 VAMP2
12 external side of plasma membrane GO:0009897 9.43 CCR7 CD27 CD40LG CD79A IL13 IL2RA
13 SNARE complex GO:0031201 9.1 SNAP23 SNAP25 STX3 VAMP2 VAMP3 VAMP7
14 plasma membrane GO:0005886 10.17 CCR7 CD27 CD40LG CD79A IL2RA LTA
15 extracellular region GO:0005576 10.16 CD27 CD40LG IFNG IL10 IL13 IL2
16 extracellular space GO:0005615 10.15 CD40LG IFNG IL10 IL13 IL2 IL4

Biological processes related to Tetanus according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 CD27 CD79A IFNG IL2RA
2 vesicle-mediated transport GO:0016192 9.98 NSF STX3 VAMP2 VAMP3 VAMP7
3 response to lipopolysaccharide GO:0032496 9.95 CCR7 IL10 IL13 LTA
4 negative regulation of inflammatory response GO:0050728 9.87 IL10 IL2 IL2RA
5 B cell differentiation GO:0030183 9.86 CD40LG CD79A IL10 IL4
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 CD27 CD40LG LTA
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 IFNG IL13 IL2 IL4
8 positive regulation of T cell proliferation GO:0042102 9.83 CD40LG IL2 IL2RA IL4
9 cytokine-mediated signaling pathway GO:0019221 9.8 IL10 IL13 IL2 IL2RA IL4 IL5
10 negative regulation of endothelial cell apoptotic process GO:2000352 9.79 IL10 IL13 IL4
11 long-term synaptic potentiation GO:0060291 9.78 MPP2 SNAP25 STX3 VAMP2
12 B cell proliferation GO:0042100 9.77 CD40LG CD79A IL10
13 positive regulation of B cell proliferation GO:0030890 9.76 IL13 IL2 IL4 IL5
14 regulation of signaling receptor activity GO:0010469 9.76 CD40LG IFNG IL10 IL13 IL2 IL4
15 calcium ion regulated exocytosis GO:0017156 9.75 VAMP2 VAMP3 VAMP7
16 positive regulation of interleukin-12 production GO:0032735 9.74 CCR7 CD40LG IFNG
17 membrane fusion GO:0061025 9.73 SNAP23 STX3 VAMP2 VAMP3
18 regulation of regulatory T cell differentiation GO:0045589 9.72 IFNG IL2 IL2RA
19 vesicle fusion GO:0006906 9.71 SNAP23 SNAP25 STX3 VAMP7
20 negative regulation of growth of symbiont in host GO:0044130 9.69 IL10 LTA
21 positive regulation of receptor recycling GO:0001921 9.69 NSF VAMP3
22 synaptic vesicle fusion to presynaptic active zone membrane GO:0031629 9.69 SNAP23 SNAP25 STX3
23 synaptic vesicle priming GO:0016082 9.68 SNAP23 SNAP25
24 interleukin-2-mediated signaling pathway GO:0038110 9.68 IL2 IL2RA
25 synaptic vesicle docking GO:0016081 9.68 SNAP25 STX3
26 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 IL2 IL4
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 IL4
28 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL2 IL5 VAMP3
29 Golgi to plasma membrane protein transport GO:0043001 9.67 NSF VAMP2 VAMP3 VAMP7
30 SNARE complex assembly GO:0035493 9.66 VAMP3 VAMP7
31 natural killer cell degranulation GO:0043320 9.66 VAMP2 VAMP7
32 negative regulation of lymphocyte proliferation GO:0050672 9.65 IL2 IL2RA
33 exocytic insertion of neurotransmitter receptor to postsynaptic membrane GO:0098967 9.64 SNAP25 STX3
34 eosinophil degranulation GO:0043308 9.64 VAMP2 VAMP7
35 mucus secretion GO:0070254 9.63 VAMP2 VAMP3
36 regulation of isotype switching GO:0045191 9.63 IL10 IL4
37 type 2 immune response GO:0042092 9.62 IL10 IL4
38 positive regulation of T cell differentiation GO:0045582 9.62 CD27 IL2 IL2RA IL4
39 negative regulation of complement-dependent cytotoxicity GO:1903660 9.61 IL13 IL4
40 regulation of histamine secretion by mast cell GO:1903593 9.61 VAMP2 VAMP3
41 regulation of T cell homeostatic proliferation GO:0046013 9.6 IL2 IL2RA
42 exocytosis GO:0006887 9.5 NSF SNAP23 SNAP25 STX3 VAMP2 VAMP3
43 immune response GO:0006955 9.32 CCR7 CD40LG IFNG IL10 IL13 IL2
44 negative regulation of apoptotic process GO:0043066 10.09 CD27 CD40LG IL10 IL2 IL4
45 inflammatory response GO:0006954 10.05 CCR7 CD40LG IL10 IL13 IL5

Molecular functions related to Tetanus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.71 IL10 IL2 IL4 IL5
2 SNARE binding GO:0000149 9.62 NSF STX3 VAMP2 VAMP7
3 SNAP receptor activity GO:0005484 9.56 SNAP23 SNAP25 STX3 VAMP7
4 syntaxin-1 binding GO:0017075 9.46 NSF SNAP25 VAMP2 VAMP3
5 syntaxin binding GO:0019905 9.35 NSF SNAP23 SNAP25 VAMP2 VAMP7
6 cytokine activity GO:0005125 9.23 CD40LG IFNG IL10 IL13 IL2 IL4
7 protein binding GO:0005515 10.32 CD27 CD40LG CD79A IFNG IL10 IL13

Sources for Tetanus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....